{"id":"W2792603138","doi":"10.1097/coc.0000000000000429","title":"Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma","year":2018,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Chugai Pharmaceutical; National Institutes of Health; Astellas Pharma; University of Pennsylvania; Ariad Pharmaceuticals; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Discontinuation; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Gastroenterology; Carcinoma; Surgery; Oncology; Progressive disease; Cancer; Disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005049345,0.0001385693,0.001329114,0.00006292645,0.00005527138,0.00000313647,0.0001210999,0.00006195909,0.0000773736],"category_scores_gemma":[0.0003692131,0.00006754608,0.0006178835,0.0001242254,0.0008532041,0.00002897762,0.00001219354,0.000117459,0.000006067178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001032222,"about_ca_system_score_gemma":0.0005685371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007564044,"about_ca_topic_score_gemma":0.00002566113,"domain_scores_codex":[0.998072,0.0001744731,0.001216612,0.0001573721,0.0001741588,0.0002053808],"domain_scores_gemma":[0.9933497,0.004511449,0.001263342,0.0002605583,0.0003996335,0.0002153494],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01371867,0.003142213,0.4765628,0.000006348474,0.000733331,0.0001369311,0.0002592727,0.000002467201,0.00001296269,0.00009795836,0.000897138,0.5044299],"study_design_scores_gemma":[0.01527405,0.2102873,0.6792327,0.00003103737,0.0009615473,0.00046882,0.0003499776,0.00003901077,0.0003538155,0.0001112166,0.09282976,0.00006071016],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911855,0.001103008,0.0001155189,0.005393848,0.0008118607,0.0003511952,0.00001153354,0.00000484641,0.001022717],"genre_scores_gemma":[0.9910496,0.002189789,0.003993691,0.0008952226,0.001742091,0.00002333935,0.000003202532,0.000015886,0.00008721965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5043692,"threshold_uncertainty_score":0.3143666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08574078329257076,"score_gpt":0.4604282430723585,"score_spread":0.3746874597797878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}